effectiveness safety tenofovir gel antiretroviral microbicide prevention hiv infection women 
centre aids program research south africa caprisa trial assessed effectiveness safety % vaginal gel formulation tenofovir nucleotide reverse transcriptase inhibitor prevention hiv acquisition women double-blind randomized controlled trial conducted comparing tenofovir gel n women placebo gel n women sexually active hiv-uninfected year-old women urban rural kwazulu-natal south africa hiv serostatus safety sexual behavior gel condom use assessed monthly follow-up visits months hiv incidence tenofovir gel arm per women-years person time study observation women-years compared per women-years women-years placebo gel arm incidence rate ratio p high adherers gel adherence > % hiv incidence % lower p tenofovir gel arm intermediate adherers gel adherence % low adherers gel adherence < % hiv incidence reduction % respectively tenofovir gel reduced hiv acquisition estimated % overall % women high gel adherence increase overall adverse event rates observed changes viral load tenofovir resistance hiv seroconverters tenofovir gel potentially fill important hiv prevention gap especially women unable successfully negotiate mutual monogamy condom use 
